• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Saudi Journal of Gastroenterology >Concurrent autoimmune hepatitis and grave's disease in Hepatitis C during pegylated Interferon α-2a and ribavirin therapy
【24h】

Concurrent autoimmune hepatitis and grave's disease in Hepatitis C during pegylated Interferon α-2a and ribavirin therapy

机译：聚乙二醇化干扰素α-2a和利巴韦林治疗期间同时发生的丙型肝炎自身免疫性肝炎和严重疾病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Classical interferon-α has been shown to be associated with the development of a variety of autoimmune disorders. A 34-year-old white woman with chronic hepatitis C virus infection who was treated with pegylated interferon α-2a and ribavirin, developed Grave's disease and autoimmune hepatitis (AIH) at 32 and 44 weeks, respectively, following initiation of the therapy. The diagnosis of AIH was made based on the new development of anti-smooth muscle antibodies, anti-mitochondrial antibodies, and liver biopsy findings. It was confirmed by positive response to steroid challenge and was assessed according to the international AIH scoring system. Based on the previous case reports, we review the existing literature. Clinicians should be aware of the possibility of multiple autoimmune disorders during interferon-based therapy for chronic hepatitis.
机译：已证明经典干扰素-α与多种自身免疫性疾病的发展有关。开始治疗后，接受聚乙二醇干扰素α-2a和利巴韦林治疗的一名患有慢性丙型肝炎病毒感染的34岁白人妇女，分别在治疗开始后的32周和44周出现了Grave病和自身免疫性肝炎（AIH）。 AIH的诊断是基于抗平滑肌抗体，抗线粒体抗体和肝活检结果的新进展而做出的。它通过类固醇激发的积极反应得到证实，并根据国际AIH评分系统进行了评估。基于以前的案例报告，我们回顾了现有文献。临床医生应意识到在以干扰素为基础的慢性肝炎治疗期间可能会出现多种自身免疫性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号